Phonak US opens new audiology research centre

21 December 2014 (Last Updated December 21st, 2014 18:30)

Phonak US has opened a new centre for innovation, audiology and clinical research in North America.

Image

Phonak US has opened a new centre for innovation, audiology and clinical research in North America.

Research undertaken at the Phonak Audiology Research Park (PARC) will meet the requirements of US hearing care professionals.

It offers professionals proof-based science to support best-practice clinical protocols that result in increased adoption of hearing technology.

Current adoption rate of hearing devices among US consumers with some degree of hearing loss is only 25%. An average of seven years is expected to treat hearing loss.

"The partnership between Phonak audiology and engineering represents a multi-disciplinary approach, designed to advance the understanding of hearing loss and discover new applications of hearing technology performance."

The partnership between Phonak audiology and engineering represents a multi-disciplinary approach, designed to advance the understanding of hearing loss and discover new applications of hearing technology performance.

Researchers at Phonak are finding the limits of hearing instrument functionalities in real life using the PARC Listening Loft, as well using a patient testing facility with the latest measurement capabilities.

Phonak Clinical Research senior manager Aniket Saoji said: "The Listening Loft environment replicates the living areas of a home and allows us to test hearing technology in a realistic and natural environment."

The PARC is also home to pediatric product validation efforts, led by Phonak Pediatric Clinical Research director Christine Jones.

Phonak, a member of the Sonova Group, has been developing, producing and distributing hearing systems and wireless devices for more than 60 years.


Image: Lori Rakita, a research audiologist at the new Phonak US Audiology Research Center (PARC) conducts a hearing test on a patient as part of a larger clinical study at the PARC. Photo: courtesy of PRNewswire.